Open Orphan

We have changed our name to hVIVO plc, ticker: HVO. Follow @hVIVO_UK to keep up to date.

[Open Orphan @OpenOrphan]

We are planning to change our name to #hVIVO plc on 26 October 2022

✅Better reflects our core human challenge & early clinical services business
✅ @hVIVO_UK name = strong brand recognition
✅Aligning with hVIVO's long & established heritage

https://t.co/vyab0r9kFI

#HVO #ORPH

[hVIVO @hVIVO_UK]

Reminder we are holding a Capital Markets Day tomorrow at 9.30 am - 12.00 pm.
🧑Chaired by our #CEO
🔬 Insights into the business
📈 Human challenge trials & the growing market
🗣️ Guest speakers, including @p_openshaw
❓ Q&A with management

Register:
https://t.co/fF4ffjzMPL

[Open Orphan @OpenOrphan]

Make sure you follow @hVIVO_UK for company updates…

[hVIVO @hVIVO_UK]

Welcome our new followers 👋.

If you would like to receive alerts📣 on all #hVIVO investor news, you can sign up to our email alert’s 📧 here:
https://t.co/SBK8wRYUx3

#HVO #Alert #Investors

[hVIVO @hVIVO_UK]

Our #CEO caught up with @BRR_Media to discuss the name change from @OpenOrphan to hVIVO plc. Learn more on why #hVIVO made this strategic business decision.

https://t.co/15b4ga9OlZ

Our ticker has changed to #HVO

Follow👉@hVIVO_UK to keep up to date!

[Open Orphan @OpenOrphan]

Today we officially change our name to hVIVO on @LSEGplc AIM and @euronext_ie📣

Find all the latest news & investor information here:
https://t.co/0uzYYHdPun

👉Don’t forget to start following @hVIVO_UK.

📈 Our new ticker is #HVO

[Open Orphan @OpenOrphan]

Further to our recent announcement, #ORPH's name change to hVIVO plc has now been completed and is expected to take effect on @LSEGplc AIM & @euronext_ie from 8.00 am tomorrow.

Learn more:

https://t.co/3Sb7Rns0gj

Follow us on @hVIVO_UK to keep up to date!

#HVO

[Open Orphan @OpenOrphan]

Last week we announced our upcoming Capital Markets Day on Wednesday 2 November 2022 at 9.30 am - 12.00 pm (GMT).

Register below if you would like to attend virtually ⏬

https://t.co/YdJeYdydUy

#HVO #CapitalMarketsDay #ORPH

[Open Orphan @OpenOrphan]

Reminder to follow @hVIVO_UK to keep up to date with company & industry news…

[hVIVO @hVIVO_UK]

The @heraldscotland reports on the rate of #flu #infection more than doubling at this time of the year, highlighting the importance of #influenza research.

@hVIVO_UK has over 15 years in conducting influenza human challenge studies.

https://t.co/mTYqNiV7rT

✍️@HMcardleHT #HVO

[Open Orphan @OpenOrphan]

We're holding a Capital Markets Day on 2 Nov 2022.

🧑Chaired by our #CEO
🔬 Insights into the business
📈 Human challenge trials & the growing market
🗣️ Guest speakers, including @p_openshaw
❓ Q&A with #ORPH management

https://t.co/1WDLll4Tcq

#HVO

[Open Orphan @OpenOrphan]

Yesterday's announcement on the appointment of Stephen Pinkerton as #CFO and Executive Director, featured in @CityAM.

Read full #article below:

https://t.co/6TKE3SEYFW

✍️@Mendelpol #HVO #hVIVO #leadership

Reminder: Follow @hVIVO_UK for future company updates

[Open Orphan @OpenOrphan]

Following this mornings announcement on Stephen Pinkerton's appointment as #CFO & Executive Director for the group, he caught up with @VoxPodcast to discuss his experience & how this change aligns with the company's growth

Tune in👂
https://t.co/V5uuKIYsPv

#HVO

[Open Orphan @OpenOrphan]

Stephen Pinkerton has been appointed as #CFO and Exec Director of #ORPH.

Wealth of experience:

☑️ 25 years in Senior Financial Roles

☑️ Served as Commercial Financial Director @hVIVO_UK since 2017 driving initiatives to improve profitability

https://t.co/GKRY0edd57

#HVO

[Open Orphan @OpenOrphan]

Follow @hVIVO_UK & keep up to date with company & industry news...#HVO

[hVIVO @hVIVO_UK]

Interesting article in The @Independent on increased #flu activity in the #US, following low #vaccination rates, with a particular focus on #Texas & #Georgia already suffering from high levels of #influenza.

Read more:
https://t.co/YJnML9XUi2

#HVO #infectiousdisease #hVIVO

[hVIVO @hVIVO_UK]

Yesterday was a great day at the @vaccinenation 2022 #Europe event, held in the beautiful city of #Barcelona.

Our #CFO presented "Utilising human challenge models to advance vaccine development"

We are located at stand 67, come and join us! 👋

#hVIVO #HVO

[Open Orphan @OpenOrphan]

Make sure you follow @hvivo_uk to keep up to date with all company news following our name change on 26 Oct 2022.

[hVIVO @hVIVO_UK]

We plan to have 2 #logos to represent #Corporate social media posts and #Investor related social media posts.

Make sure you follow us to keep up to date with all investor related news following our name change, going into effect on 26 Oct 2022.

#HVO

[Open Orphan @OpenOrphan]

As part of our company name change to hVIVO, our social media will be moving across to the @hVIVO_UK socials. Make sure you follow #hVIVO to keep up to date with company newsflow.

See you there 👋! The name change countdown is on...⏲️

#HVO

[hVIVO @hVIVO_UK]

We will be attending next week's World Vaccine Congress in #Barcelona. Stop by stand #67 to learn more about our challenge models, lab services & Vaccine Studies.

Our #CSO will be presenting during the event & look forward to seeing our industry colleagues

#WVC2022 #WVCEurope

[Open Orphan @OpenOrphan]

We announced that we will be changing our name from Open Orphan to #hVIVO on 26 Oct 2022. Our ticker will be changing from #ORPH to #HVO.

Watch below to see reasons why we decided to make this strategic business decision...

Follow @hVIVO_UK to keep up to date!

[Open Orphan @OpenOrphan]

Our new investors section will be going live alongside our name change launch, which is expected to take place on 26 October 2022.

Stay tuned...👀 and don't forget to follow @hVIVO_UK for updates

#WatchThisSpace #StayTuned #Rebrand #HVO #hVIVO #ORPH

[Open Orphan @OpenOrphan]

Positive #data from a peer-reviewed study evaluating the in vitro efficacy of FLU-v, @ImutexLtd broad spectrum #influenza #vaccine candidate, has been published in the scientific journal @Vaccines.

Learn more:

https://t.co/yujXabrazu

#HVO #Imutex #Flu #ORPH